Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration

被引：9

作者：

Booton, R ^{[1
]}

Thatcher, N ^{[1
]}

机构：

[1] Christie Hosp NHS Trust, Dept Med Oncol, CRC, Manchester M20 4BX, Lancs, England

来源：

CURRENT OPINION IN ONCOLOGY | 2002年 / 14卷 / 02期

关键词：

D O I：

10.1097/00001622-200203000-00009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations. (C) 2002 Lippincott Williams Wilkins, Inc.

引用

页码：191 / 198

页数：8

共 45 条

[1] Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study [J].

Ackland, SP ;

Anton, A ;

Breitbach, GP ;

Colajori, E ;

Tursi, JM ;

Delfino, C ;

Efremidis, A ;

Ezzat, A ;

Fittipaldo, A ;

Kolaric, K ;

Lopez, M ;

Viaro, D .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :943-953

[2]

Ahn AB, 2000, AM J CLIN ONCOL-CANC, V23, P622

[3]

ALBERTI W, 1995, BRIT MED J, V311, P899

[4] Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].

Anderson, H. ;

Hopwood, P. ;

Stephens, R. J. ;

Thatcher, N. ;

Cottier, B. ;

Nicholson, M. ;

Milroy, R. ;

Maughan, T. S. ;

Falk, S. J. ;

Bond, M. G. ;

Burt, P. A. ;

Connolly, C. K. ;

McIllmurray, M. B. ;

Carmichael, J. .

BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453

[5]

Belani C, 2001, SEMIN ONCOL, V28, P10, DOI [10.1053/sonc.2001.24602, 10.1053/sonc.20901.18403]

[6] Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].

Bonomi, P ;

Kim, KM ;

Fairclough, D ;

Cella, D ;

Kugler, J ;

Rowinsky, E ;

Jiroutek, M ;

Johnson, D .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631

[7] Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].

Breathnach, OS ;

Freidlin, B ;

Conley, B ;

Green, MR ;

Johnson, DH ;

Gandara, DR ;

O'Connell, M ;

Shepherd, FA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742

[8] Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer [J].

Cardenal, F ;

López-Cabrerizo, MP ;

Antón, A ;

Alberola, V ;

Massuti, B ;

Carrato, A ;

Barneto, I ;

Lomas, M ;

García, M ;

Lianes, P ;

Montalar, J ;

Vadell, C ;

González-Larriba, JL ;

Nguyen, B ;

Artal, A ;

Rosell, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :12-18

[9] Non-small-cell lung cancer - Stalemate or progress? [J].

Carney, DN ;

Hansen, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (17) :1261-1262

[10] Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer [J].

Comella, P .

SEMINARS IN ONCOLOGY, 2001, 28 (02) :7-10

← 1 2 3 4 5 →